The Lynx Group
Cholangiocarcinoma News

Genomic Testing in Cholangiocarcinoma: Look for Actionable Molecular Alterations

December 2020, Vol 1, No 3

At the 2020 Cholangiocarcinoma Summit, Nabeel El-Bardeesy, PhD, Associate Professor, Medicine, Harvard Medical School, and Associate Geneticist, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, moderated a session titled “Molecular Biomarkers in CCA: Focus on Current and Emerging Technologies.” The session focused on how best to integrate the array of genomic testing platforms into clinical practice. The session included 2 presenters who discussed this topic.

Kenna R. Mills Shaw, PhD, Executive Director, Khalifa Institute for Personalized Cancer Therapy, M.D. Anderson Cancer Center, Houston, pointed out the difficulties in operationalizing precision medicine.

“We see over 100,000 patients a year and we perform over 20,000 molecular tests across our leukemia and solid tumor patient populations. When we started to look very discreetly at the number of molecular results that were utilized for treatment decisions in our patient population a few years ago, we found that it was a very small number of patients,” Dr Mills Shaw said.

“On a 46- and 50-gene hotspot panel, when we looked at 2000 patients that were not getting tested for standard of care but were looking for clinical trial opportunities, we found that only about 4% of our patient population overall—4% of the 2000—or just about 11% of the patients with a mutation and an actionable gene, were ultimately matched to a therapeutic target. This is, of course, concerning to us, as we wanted to try to inform or push forward precision medicine,” Dr Mills Shaw added.

She cautioned that regardless of how much of the genomic landscape is being sequenced, oncologists are still working with only a very small amount of an actionable genome. Her advice for oncologists is to make sure that they understand what’s being tested, what’s on the panel, what’s not on the panel, and what’s not included in the assay so the data can be properly interpreted.

Next-Generation Sequencing in Cholangiocarcinoma

Afsaneh Barzi, MD, PhD, Clinical Medical Director, Access Hope, and Associate Professor, Clinical Medicine-Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, focused her discussion on next-generation sequencing in cholangiocarcinoma (CCA) and the challenges in interpreting these data.

“My own sense is that it’s just not enough to say what we see on these reports. It’s also important to know what we’re not seeing on these reports, and whether that requires additional testing, or whether we should pay attention to what is unknown. It’s important to familiarize yourself with the report you’re commonly using,” Dr Barzi said.

She highlighted the importance of fusions and translocations as drivers in CCA. Maximizing the detection of such fusions enhances the benefit of precision medicine for various solid tumors. However, Dr Barzi noted that DNA-based next-generation sequencing can miss some fusions.

“The majority of these missed fusions were actionable. This only tells us that by looking at the DNA only, you may be actually missing some of these fusions. As clinicians, we have to be aware of it and look at alternatives to answer a clinical question,” Dr Barzi advised.

She emphasized that maximizing the rate of variant diagnosis for targeted therapy relies on precise identification of common and rare fusions. RNA sequencing yields information beyond what conventional DNA next-generation sequencing alone can provide. The addition of RNA sequencing will enhance the detection of targetable fusions and translocations in patients with intrahepatic CCA, she said.

“Don’t be satisfied with the results if you think there is something that can change the outcome. Always reach out to the labs who are doing the tests. They have resources that can help with interpretation of the results,” Dr Barzi concluded.

Related Items

Phase 1 Results of Gunagratinib in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations
2021 Year in Review: Cholangiocarcinoma
A phase 1/2a, first-in-human clinical study demonstrated that the highly selective, irreversible pan-FGFR inhibitor gunagratinib was safe and well-tolerated in patients with advanced solid tumors, including CCA.
Prognostic Value of FGFR2 Alterations in Patients Receiving Systemic Chemotherapy for Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis indicated the prognostic value of FGFR2 fusions/rearrangements in patients with intrahepatic CCA receiving systemic chemotherapy, which warrants additional study.
FGFR2 Fusion and/or Rearrangement Profiling in Chinese Patients with Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
A Comprehensive Genomic and Immune Profiling Study of IDH1- and IDH2-Driven Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A comprehensive genomic and immune characterization of IDH-mutated and wild-type intrahepatic CCA revealed significant differences in genetic alterations.
Characteristics of IDH Mutations in Bile Duct Carcinoma in a Chinese Population
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis in a large Chinese patient cohort with bile duct carcinoma indicated that activating IDH1/2 mutations occurred at a lower rate compared with that previously reported in the global population.
Silmitasertib (CX-4945) plus Gemcitabine and Cisplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic CCA
2021 Year in Review: Cholangiocarcinoma
Preliminary evidence suggests that combination treatment with silmitasertib plus gemcitabine/cisplatin as first-line therapy has promising efficacy and a favorable safety profile in patients with locally advanced or metastatic CCA.
Targeted Therapies in CCA: Assessment of US Oncologist Practice Patterns
2021 Year in Review: Cholangiocarcinoma
Findings from a clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and the use of targeted therapies in patients with unresectable CCA, underscoring the important role of education in overcoming these gaps.
First-Line Toripalimab plus Lenvatinib in Combination with GemOx Chemotherapy for Advanced Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Results of a phase 2 study indicate that toripalimab and lenvatinib in combination with GemOx chemotherapy provide antitumor activity and reasonable tolerability in patients with advanced intrahepatic CCA.
Comparative Landscape of Actionable Somatic Alterations in Advanced CCA from Circulating Tumor and Tissue-Based DNA Profiling
2021 Year in Review: Cholangiocarcinoma
Findings from a retrospective analysis support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic Cholangiocarcinoma and IDH1 Mutation
By Loretta Fala
2021 Year in Review: Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile duct that forms inside the liver (ie, intrahepatic) or outside the liver (ie, extrahepatic, including perihilar and distal tumors). Individuals with colitis or certain liver diseases may have an increased risk for CCA. Although the precise incidence of CCA is unknown, an estimated 8000 new cases of CCA are diagnosed annually in the United States. It is likely, however, that this number is higher, because CCA is difficult to diagnose and may be misclassified at times.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: